Slides: The benefits of icosapent ethyl in addressing residual risk: What is the evidence?
Find here the slides of the presentation by Lale Tokgözoğlu, titled "The benefits of icosapent ethyl in addressing residual risk: What is the evidence?".
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
Share this page with your colleagues and friends: